[News Brief] OneSource-Hikma Partnership Secures Approval for Generic Ozempic in Saudi Arabia
OneSource Specialty Pharma has received regulatory approval in Saudi Arabia to commercialise a generic version of Ozempic® (semaglutide) in collaboration…
Global Pharmaceuticals & Supplements
[News Brief] ImmunityBio to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Treatment
ImmunityBio has partnered with Biopharma and Cigalah Healthcare to commercialise ANKTIVA® (nogapendekin alfa inbakicept) in Saudi Arabia for bladder and…
[News Brief] Pharmapack Announces Expansion to Asia with Singapore Event in November 2026
Pharmapack Europe has announced the launch of a new Pharmapack Asia event in Singapore, slated for November 2026, offering a…
[News Brief] GSK: Arexvy Linked to Lower RSV-Related Cardiopulmonary Risks
GSK has published findings indicating its respiratory syncytial virus (RSV) vaccine Arexvy was associated with reduced risks of certain severe…
[News Brief] ViiV Healthcare Reports Better Outcomes for Long-Acting HIV Therapy
ViiV Healthcare has reported that final data from the LATITUDE phase III trial show its long-acting injectable regimen, Cabenuva (cabotegravir…
[News Brief] Otsuka Pharmaceutical Co., Ltd. Announces FDA Priority Review of Centanafadine NDA for ADHD
Otsuka has stated that the U.S. Food and Drug Administration (FDA) has accepted for priority review its New Drug Application…
[News Brief] Novo Nordisk Secures EU Approval for 7.2 mg Wegovy Dose
The European Commission has approved a 7.2 mg once-weekly maintenance dose of Wegovy® (semaglutide) for adults with obesity across all…
[News Brief] Sanofi’s Tzield Accepted for Priority Review in the US for Young Children with Stage 2 Type 1 Diabetes
Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics licence…
[News Brief] Takeda Releases Phase 3 Data for Zasocitinib in Plaque Psoriasis
Takeda has published results from its Phase 3 clinical trials for Zasocitinib, an oral treatment for moderate-to-severe plaque psoriasis. This…